Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest ...

Novo Nordisk (NVO) has reportedly launched its popular weight-loss drug Wegovy in China ahead of a rival drug by Eli Lilly ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

Novo Nordisk's Wegovy launch in China begins in Shanghai at $194 per four-injection pack, significantly cheaper than U.S.

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

About 400 people marched to the South African headquarters of Novo Nordisk A/S in Johannesburg this week demanding greater ...

(Bloomberg) -- Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a ...

Polen Capital, an investment management company, released its “Polen Global Growth Strategy” third-quarter 2024 investor ...

After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its ...

Omega Therapeutics is halting work on its only clinical-stage candidate as part of a strategic refocus centered on three ...

Polen Global Growth Strategy highlighted stocks like Novo Nordisk A/S (NYSE:NVO), in the Q3 2024 investor letter. Novo Nordisk A/S (NYSE:NVO) engages in the research and development, manufacture ...